Investing.com – Medtronic (NYSE: MDT)

Medtronic reported second quarter EPS of $1.26, surpassing the analyst estimate of $1.25 by $0.01. Revenue for the quarter reached $8.4B, exceeding the consensus estimate of $8.28B.

Guidance

Medtronic anticipates FY 2025 EPS between $5.44 and $5.50, compared to the analyst consensus of $5.45.

Medtronic's stock price closed at $87.59, showing a -0.27% decline over the last 3 months but a 16.54% increase over the past 12 months.

In the last 90 days, Medtronic experienced 2 positive EPS revisions and 18 negative revisions. For a historical perspective, see Medtronic's stock price reactions to earnings.

According to InvestingPro, Medtronic's Financial Health score reflects "good performance".

Stay informed about upcoming earnings reports by checking Investing.com's earnings calendar.